Chronic kidney disease as a situation of high added risk in hypertensive patients

Journal of the American Society of Nephrology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Segura, Julian ^a   García Donaire, Jose A ^a   Praga, Manuel ^a   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; STATINE DERIVATIVE;

ANEMIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DYSLIPIDEMIA; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SMOKING CESSATION;

EID: 33645463031     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005121330     Document Type: Conference Paper

References (51)

1. Chobanian A, Bakris GL, Black HR, Cushman W, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella E: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289: 2560-2572, 2003
2. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003
3. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher T: Renal function: The Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38: 1782-1787, 2001
4. Sarnak MJ, Levey AS, Schollwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
5. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56: 2214-2219, 1999
6. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12, 2003
7. Clase CM, Garg AX, Kiberd BA: Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination survey (NHANES III). J Am Soc Nephrol 13: 1338-1349, 2002
8. Segura J, Campo C, Ruilope LM: How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens (Greenwich) 4: 332-336, 2002
9. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004
10. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M: Chronic kidney disease and cardiovascular disease in a general Japanese population: The Hisayama Study. Kidney Int 68: 228-236, 2005
11. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 44: 198-206, 2004
12. Segura J, Campo C, Gil P, Roldan C, Vigil L, Rodicio JL, Ruilope LM: Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 15: 1616-1622, 2004
13. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn study. Arterioscler Thromb Vasc Biol 19: 617-624, 1999
14. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300: 297-300, 1990
15. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: A systematic overview of the literature. Arch Intern Med 157: 1413-1418, 1997
16. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 286: 421-426, 2001
17. Jensen JS, Feldt-Rasmussen B, Strangaard S, Schroll M, Borch-Johnsen K: Arterial hypertension, microalbuminuria and risk of ischemic heart disease. Hypertension 35: 898-903, 2000
18. Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16: 1325-1333, 1998
19. Agewall S, Wikstrand J, Ljungman S, Fagerberg B: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 80: 164-169, 1997
20. Roest M, Banga JD, Janssen WM, Grobbee DE, Sixma JJ, de Jong PD, de Zeeuw D, van Der Schouw YT: Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 103: 3057-3061, 2001
21. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 106: 1777-1782, 2002
22. Redon J, Williams B: Microalbuminuria in essential hypertension: Redefining the threshold. J Hypertens 20: 353-355, 2002
23. Segura J, Campo C, Ruilope LM: Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 66: S45-S49, 2004
24. Fesler P, Du Cailar G, Ribstein J, Mimran A: Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 14: 881-887, 2003
25. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114: 345-352, 1991
26. Volpe M, Alderman MH, Furberg CD, Jackson R, Kostis JB, Laragh JH, Psaty BM, Ruilope LM: Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens 17: 1068-1074, 2004
27. Turnbull F: Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362: 1527-1535, 2003
28. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363: 2022-2031, 2004
29. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290: 2805-2816, 2003
30. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218-1226, 2005
31. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S; A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial. Lancet 364: 849-857, 2004
32. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 292: 2217-2225, 2004
33. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F: Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 45: 907-913, 2005
34. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7-22, 2002
35. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003
36. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351: 1755-1762, 1998
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001
38. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001
39. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A; Brisighella Heart Study Working Party: Association between different lipid-lowering treatment strategies, blood pressure control in the Brisighella Heart Study. Am Heart J 148: 285-292, 2004
40. Anavekar NS, Pfeffer MA: Cardiovascular risk in chronic kidney disease. Kidney Int Suppl 92: S11-S15, 2004
41. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML; APPROACH Investigators: The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44: 1587-1592, 2004
42. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004
43. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563, 2004
44. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57: 728-734, 2004
45. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC: Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112: 171-178, 2005
46. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns HS, Collins R, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC: First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473-484, 2005
47. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ: Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144: 226-232, 2002
48. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42: 201-208, 2003
49. Curtis BM, Levin A, Parfrey PS: Multiple risk factor intervention in chronic kidney disease: Management of cardiac disease in chronic kidney disease patients. Med Clin North Am 89: 511-523, 2005
50. Segura J, Campo C, Ruilope LM: Chronic kidney disease and global cardiovascular risk in essential hypertension. Minerva Med 95: 375-383, 2004
51. Fioretto P, Solini A: Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol 16[Suppl 1]: S18-S21, 2005